CSCO黑色素瘤诊疗指南解读——前哨淋巴结活检的意义、操作及治疗专家共识

2021-09-15 中国临床肿瘤学会 临床肿瘤学杂志

黑色素瘤是一类起源于黑色素细胞的高度恶性肿瘤,近年来我国乃至全球范围内其发病率均不断上升,临床中此类疾病的诊疗规范化就显得尤为重要。

中文标题:

CSCO黑色素瘤诊疗指南解读——前哨淋巴结活检的意义、操作及治疗专家共识

发布机构:

中国临床肿瘤学会

发布日期:

2021-09-15

简要介绍:

黑色素瘤是一类起源于黑色素细胞的高度恶性肿瘤,近年来我国乃至全球范围内其发病率均不断上升,临床中此类疾病的诊疗规范化就显得尤为重要。黑色素瘤的治疗及预后与肿瘤的分期密切相关,而患者是否伴有淋巴结转移是准确分期的重要依据。前哨淋巴结活检是判定淋巴结隐匿转移的最佳手段。本共识的撰写目的主要在于向临床医师阐释我国临床推广黑色素瘤前哨淋巴结活检的重要意义,并为其提供统一、规范且可操作性较强的具体指导建议。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=CSCO黑色素瘤诊疗指南解读_前_省略_结活检的意义_操作及治疗专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=055d61c002252ed1, title=CSCO黑色素瘤诊疗指南解读——前哨淋巴结活检的意义、操作及治疗专家共识, enTitle=, guiderFrom=临床肿瘤学杂志, authorId=0, author=, summary=黑色素瘤是一类起源于黑色素细胞的高度恶性肿瘤,近年来我国乃至全球范围内其发病率均不断上升,临床中此类疾病的诊疗规范化就显得尤为重要。, cover=https://img.medsci.cn/2021113/1635954838791_1608702.jpg, journalId=0, articlesId=null, associationId=2095, associationName=中国临床肿瘤学会, associationIntro=中国临床肿瘤学会(CSCO)黑色素瘤专家委员会, copyright=0, guiderPublishedTime=Wed Sep 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">黑色素瘤是一类起源于黑色素细胞的高度恶性肿瘤,近年来我国乃至全球范围内其发病率均不断上升,临床中此类疾病的诊疗规范化就显得尤为重要。黑色素瘤的治疗及预后与肿瘤的分期密切相关,而患者是否伴有淋巴结转移是准确分期的重要依据。前哨淋巴结活检是判定淋巴结隐匿转移的最佳手段。本共识的撰写目的主要在于向临床医师阐释我国临床推广黑色素瘤前哨淋巴结活检的重要意义,并为其提供统一、规范且可操作性较强的具体指导建议。&nbsp;</span></p>, tagList=[TagDto(tagId=273, tagName=黑色素瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=39, categoryName=皮肤与性病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=273, guiderKeyword=黑色素瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5166, appHits=81, showAppHits=0, pcHits=756, showPcHits=5085, likes=1, shares=12, comments=4, approvalStatus=1, publishedTime=Tue Nov 16 23:56:36 CST 2021, publishedTimeString=2021-09-15, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Wed Nov 03 23:57:49 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 21:32:10 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=CSCO黑色素瘤诊疗指南解读_前_省略_结活检的意义_操作及治疗专家共识.pdf)])
CSCO黑色素瘤诊疗指南解读_前_省略_结活检的意义_操作及治疗专家共识.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1182364, encodeId=6531118236464, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dc96151548, createdName=ms2000001737705556, createdTime=Sat Jan 08 22:04:43 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071379, encodeId=25e510e1379e4, content=谢谢上传者, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0f5719749, createdName=ms8000001197684057, createdTime=Thu Nov 18 12:15:43 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066773, encodeId=40371066e73ef, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 04 06:55:39 CST 2021, time=2021-11-04, status=1, ipAttribution=)]
    2022-01-08 ms2000001737705556

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1182364, encodeId=6531118236464, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dc96151548, createdName=ms2000001737705556, createdTime=Sat Jan 08 22:04:43 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071379, encodeId=25e510e1379e4, content=谢谢上传者, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0f5719749, createdName=ms8000001197684057, createdTime=Thu Nov 18 12:15:43 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066773, encodeId=40371066e73ef, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 04 06:55:39 CST 2021, time=2021-11-04, status=1, ipAttribution=)]
    2021-11-18 ms8000001197684057

    谢谢上传者

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1182364, encodeId=6531118236464, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dc96151548, createdName=ms2000001737705556, createdTime=Sat Jan 08 22:04:43 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071379, encodeId=25e510e1379e4, content=谢谢上传者, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0f5719749, createdName=ms8000001197684057, createdTime=Thu Nov 18 12:15:43 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066773, encodeId=40371066e73ef, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 04 06:55:39 CST 2021, time=2021-11-04, status=1, ipAttribution=)]
    2021-11-04 1207866fm50(暂无昵称)

    谢谢分享

    0

拓展阅读

2010 CCO建议 躯干或四肢皮肤黑色素瘤临床淋巴结阴性首发切除边缘和前哨淋巴结活检

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-01-01

(2010 BAD)英国皮肤黑色素瘤管理指南2010年更新版

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2010-08-01

中国黑色素瘤诊治指南2011版(修改版)

中国抗癌协会临床肿瘤学协作专业委员会(CSCO,Chinese Society of Clinical Oncology) · 2011-09-18

原发性皮肤黑色素瘤的治疗和管理的护理指南(AAD 2011)

美国皮肤病学会(AAD,American Academy of Dermatology) · 2011-11-01

2012 ESMO临床实践指南:黑色素瘤的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012 ASCO/SSO联合指南:黑色素瘤前哨淋巴结活检

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2012-07-09